Literature DB >> 22366496

Different associations of estrogen receptor β isoforms, ERβ1 and ERβ2, expression levels with tumor size and survival in early- and late-onset breast cancer.

Vesna Mandusic1, Bogomir Dimitrijevic, Dragica Nikolic-Vukosavljevic, Zora Neskovic-Konstantinovic, Ksenija Kanjer, Ute Hamann.   

Abstract

BACKGROUND: In breast cancer, little is known about the consequences of co-expression of ERα with the second estrogen receptor, ERβ, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ERα and ERβ expression levels in breast tumors.
PURPOSE: To address whether the expression ratio of ERα and ERβ and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ERβ1 to ERβ2 and ERα in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval.
RESULTS: A specific correlation of ERβ1 expression levels with tumor size was detected in early-onset breast cancer patients and of ERβ2 levels with tumor size in late-onset patients. Expression of both ERβ isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ERβ2 than ERβ1 isoform were associated with a better outcome in late-onset patients.
CONCLUSIONS: Our results suggest that different isoforms of ERβ may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22366496     DOI: 10.1016/j.canlet.2012.02.022

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression.

Authors:  Jinyou Liu; Gangadhara R Sareddy; Mei Zhou; Suryavathi Viswanadhapalli; Xiaonan Li; Zhao Lai; Rajeshwar R Tekmal; Andrew Brenner; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2018-04-16       Impact factor: 12.701

2.  ERβ Isoforms Have Differential Clinical Significance in Breast Cancer Subtypes and Subgroups.

Authors:  Young Choi; Hadong Kim; Simcha Pollack
Journal:  Curr Issues Mol Biol       Date:  2022-04-06       Impact factor: 2.976

3.  Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.

Authors:  Nalo Hamilton; Diana Márquez-Garbán; Vei Mah; Gowry Fernando; Yahya Elshimali; Hermes Garbán; David Elashoff; Jaydutt Vadgama; Lee Goodglick; Richard Pietras
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

Review 4.  Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis.

Authors:  Weige Tan; Qian Li; Kai Chen; Fengxi Su; Erwei Song; Chang Gong
Journal:  Oncotarget       Date:  2016-03-01

5.  Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study.

Authors:  Bashar Zeidan; Antigoni Manousopoulou; Diana J Garay-Baquero; Cory H White; Samantha E T Larkin; Kathleen N Potter; Theodoros I Roumeliotis; Evangelia K Papachristou; Ellen Copson; Ramsey I Cutress; Stephen A Beers; Diana Eccles; Paul A Townsend; Spiros D Garbis
Journal:  Breast Cancer Res       Date:  2018-03-22       Impact factor: 6.466

Review 6.  The role of estrogen receptor beta in breast cancer.

Authors:  Yujing Zhou; Xingdang Liu
Journal:  Biomark Res       Date:  2020-09-07

Review 7.  Estradiol Signaling at the Heart of Folliculogenesis: Its Potential Deregulation in Human Ovarian Pathologies.

Authors:  Stéphanie Chauvin; Joëlle Cohen-Tannoudji; Céline J Guigon
Journal:  Int J Mol Sci       Date:  2022-01-03       Impact factor: 5.923

Review 8.  Estrogen Receptor β Expression and Its Clinical Implication in Breast Cancers: Favorable or Unfavorable?

Authors:  Young Choi
Journal:  J Breast Cancer       Date:  2022-02-21       Impact factor: 2.922

9.  Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist.

Authors:  Yi He; Salvador Alejo; Prabhakar Pitta Venkata; Jessica D Johnson; Ilanna Loeffel; Uday P Pratap; Yi Zou; Zhao Lai; Rajeshwar R Tekmal; Edward R Kost; Gangadhara R Sareddy
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.